BIO Chairman Sees "Science-Driven" Hamburg As Plus For Regulatory Climate
Executive Summary
BIO Board Chairman Stephen Sherwin is looking forward to an improved regulatory environment at FDA for biopharmaceutical companies with the advent of Margaret Hamburg as agency commissioner